These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28032667)

  • 21. The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado-Joseph disease.
    Vasconcelos-Ferreira A; Carmo-Silva S; Codêsso JM; Silva P; Martinez ARM; França MC; Nóbrega C; Pereira de Almeida L
    Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12763. PubMed ID: 34432315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products.
    Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P
    Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.
    Oliveira Miranda C; Marcelo A; Silva TP; Barata J; Vasconcelos-Ferreira A; Pereira D; Nóbrega C; Duarte S; Barros I; Alves J; Sereno J; Petrella LI; Castelhano J; Paiva VH; Rodrigues-Santos P; Alves V; Nunes-Correia I; Nobre RJ; Gomes C; Castelo-Branco M; Pereira de Almeida L
    Mol Ther; 2018 Sep; 26(9):2131-2151. PubMed ID: 30087083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
    Hsieh M; Hsieh BY; Ma CY; Li YT; Liu CS; Lo CM
    J Neurosci Res; 2019 Oct; 97(10):1278-1297. PubMed ID: 31157458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
    Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
    Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.
    Silva-Fernandes A; Duarte-Silva S; Neves-Carvalho A; Amorim M; Soares-Cunha C; Oliveira P; Thirstrup K; Teixeira-Castro A; Maciel P
    Neurotherapeutics; 2014 Apr; 11(2):433-49. PubMed ID: 24477711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia.
    Nóbrega C; Mendonça L; Marcelo A; Lamazière A; Tomé S; Despres G; Matos CA; Mechmet F; Langui D; den Dunnen W; de Almeida LP; Cartier N; Alves S
    Acta Neuropathol; 2019 Nov; 138(5):837-858. PubMed ID: 31197505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.
    Lin GY; Ma CY; Kuo LC; Hsieh BY; Wang H; Liu CS; Hsieh M
    Metab Brain Dis; 2022 Aug; 37(6):2103-2120. PubMed ID: 35488942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
    McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
    Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
    Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
    Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nóbrega C; Carmo-Silva S; Albuquerque D; Vasconcelos-Ferreira A; Vijayakumar UG; Mendonça L; Hirai H; de Almeida LP
    Brain; 2015 Dec; 138(Pt 12):3537-54. PubMed ID: 26490332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
    Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L
    Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.
    Menzies FM; Huebener J; Renna M; Bonin M; Riess O; Rubinsztein DC
    Brain; 2010 Jan; 133(Pt 1):93-104. PubMed ID: 20007218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
    Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
    Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
    Watchon M; Luu L; Robinson KJ; Yuan KC; De Luca A; Suddull HJ; Tym MC; Guillemin GJ; Cole NJ; Nicholson GA; Chung RS; Lee A; Laird AS
    Mol Brain; 2021 Aug; 14(1):128. PubMed ID: 34416891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
    Cummings CJ; Orr HT; Zoghbi HY
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1.
    Kaemmerer WF; Low WC
    Exp Neurol; 1999 Aug; 158(2):301-11. PubMed ID: 10415138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Déglon N; de Almeida LP
    PLoS One; 2014; 9(8):e100086. PubMed ID: 25144231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
    Rajamani K; Liu JW; Wu CH; Chiang IT; You DH; Lin SY; Hsieh DK; Lin SZ; Harn HJ; Chiou TW
    Neuropharmacology; 2017 May; 117():434-446. PubMed ID: 28223212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.